US 11,685,916 B2
Systems, methods, and compositions for targeted nucleic acid editing
Feng Zhang, Cambridge, MA (US); Jonathan Gootenberg, Cambridge, MA (US); David Benjamin Turitz Cox, Cambridge, MA (US); Omar Abudayyeh, Cambridge, MA (US); and Soumya Kannan, Cambridge, MA (US)
Assigned to THE BROAD INSTITUTE, INC., Cambridge, MA (US); MASSACHUSETTS INSTITUTE OF TECHNOLOGY, Cambridge, MA (US); and PRESIDENT AND FELLOWS OF HARVARD COLLEGE, Cambridge, MA (US)
Filed by THE BROAD INSTITUTE, INC., Cambridge, MA (US); MASSACHUSETTS INSTITUTE OF TECHNOLOGY, Cambridge, MA (US); and PRESIDENT AND FELLOWS OF HARVARD COLLEGE, Cambridge, MA (US)
Filed on May 13, 2020, as Appl. No. 15/930,478.
Application 15/930,478 is a continuation of application No. 16/649,170, previously published as PCT/US2018/052247, filed on Sep. 21, 2018.
Claims priority of provisional application 62/561,669, filed on Sep. 21, 2017.
Prior Publication US 2021/0009986 A1, Jan. 14, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 15/10 (2006.01); C12N 9/22 (2006.01); A61K 38/00 (2006.01); C12N 9/78 (2006.01); C12N 9/12 (2006.01); C07K 14/295 (2006.01)
CPC C12N 15/102 (2013.01) [C12N 9/22 (2013.01); A61K 38/00 (2013.01); C07K 2319/71 (2013.01); C12Y 305/04004 (2013.01); C12Y 305/04005 (2013.01)] 6 Claims
 
1. An engineered, non-naturally occurring system comprising a catalytically inactive Cas13b effector protein (dCas13b) or a nucleotide sequence encoding the catalytically inactive Cas13b effector protein, wherein the truncated form of the Cas13b effector protein has been truncated at:
N-terminal Δ1-20, N-terminal Δ1-40, N-terminal Δ1-60, N-terminal Δ1-80, N-terminal Δ1-100, N-terminal Δ1-120, N-terminal Δ1-140, N-terminal Δ1-160, N-terminal Δ1-180, N-terminal Δ1-200, N-terminal Δ1-220, N-terminal Δ1-240, N-terminal Δ1-260, or N-terminal Δ1-300, wherein amino acid positions of the truncations correspond to amino acid positions of Prevotella sp. P5-125 Cas13b protein as set forth in SEQ ID NO: 82.